ClinicalTrials.gg
CompletedNCT01736696Updated Feb 20, 2013Results posted

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

A Phase 1 interventional study of tofacitinib and tofacitinib in Psoriasis and Immunomodulation, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-02-20.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
16th of 19
59 · median 135
Started
2002
the only one that year
Phase 1
2 of 19
1 open now
Registered
11th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 16th largest by enrollment, is the only one that started in 2002, is one of 2 in phase 1, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

03

Conditions studied

  • Psoriasis
  • Immunomodulation

Browse trials for

Keywords

  • Psoriasis
  • PASI
  • plaques
  • skin biopsy
  • immunomodulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female subjects between the ages of 18 and 65 years, inclusive, with active psoriasis lesion(s).
  • Subjects should be healthy with the exception of psoriasis, where healthy is defined as no abnormalities identified by a detailed medical history, full physical examination. Blood pressure must be \< 140/89. (BMI) between 18-36 kg/m2, inclusive; and a total body weight >50 kg (110 lbs)
  • The following laboratory variables must be no more than 10% below the lower limit of the normal reference range: RBC, , hematocrit, WBC, . The absolute lymphocyte count must be greater than or equal to the lower limit of the reference range. Values for , ALT, and alkaline phosphatase must be no more than 10% above the reference range. Values for total cholesterol and LDL must be no more than 20% above the upper limit of the normal reference range except for subjects being treated for hyperlipidemia. Normal (> 80 mL/min).

Exclusion criteria

Exclusion Criteria:

  • Subjects with evidence or history of hematological, renal, urological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic disorder.
  • Subjects with controlled essential hypertension and/or hyperlipidemia may be eligible for the study provided that any medications that are administered.
  • Screening 12-lead demonstrating at least one of the following: heart rate > 100 bpm, QRS >120 msec, > 430 msec (males), QTc > 450 msec (females) or PR > 220 msec.
  • Abnormal chest radiographs including, but not limited to, evidence of past or present tuberculosis infection. History of tuberculosis without treatment and/or positive tuberculin reaction without known vaccination with BCG.
  • Subjects with a history of tumors with the exception of adequately treated basal cell carcinoma of the skin.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    5 mg BID

    5 mg BID for 13 days and once on Day 14

    Drug: tofacitinib

  • Experimental
    10 mg BID

    10 mg BID for13 days and once on Day 14\*

    Drug: tofacitinib

  • Experimental
    20 mg BID

    20 mg BID for 13 days and once on Day 14

    Drug: tofacitinib

  • Experimental
    30 mg BID

    30 mg BID for 13 days and once on Day 14

    Drug: tofacitinib

  • Experimental
    60 mg QD

    60 mg QD for 14 days

    Drug: tofacitinib

  • Experimental
    50 mg BID

    50 mg BID x 13 days and once on day 14

    Drug: tofacitinib

Interventions

  • 5 mg BID For 13 days and once on Day 14

  • 10 mg BID for 13 days and once on Day 14\*

  • 20 mg BID for 13 days and once on Day 14

  • 30 mg BID for 13 days and once on Day 14

  • 60 mg tablet once a day (QD) for 14 days

  • 50 mg tablets two times a day (BID) for 13 days and once on day 14

06

What researchers measure

Primary outcomes

  1. Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1

    Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1

  2. Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1

  3. Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1

  4. Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1

  5. Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1

  6. Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.

    Time frame: 8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1

  7. Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.

    Time frame: Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14

  8. Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14

  9. Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14

  10. Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14

  11. Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14

  12. Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

    Time frame: 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14

  13. Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.

    Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21

  14. Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.

    Time frame: 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21

  15. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1

    AUCtau = area under the curve from time zero to end of dosing interval.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

  16. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14

    AUCtau = area under the curve from time zero to end of dosing interval.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

  17. Maximum Observed Plasma Concentration (Cmax) at Day 1

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

  18. Maximum Observed Plasma Concentration (Cmax) at Day 14

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

  19. Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1

  20. Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14

  21. Accumulation Ratio (R0)

    Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14

  22. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, 1 hr post-dose on Day 1

  23. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 2

  24. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 4

  25. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 7

  26. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 10

  27. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline; hr 0, 8 hr post-dose on Day 14

  28. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, Hour 0 on Day 18

  29. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 21

  30. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 28

  31. Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42

    Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

    Time frame: Baseline, hr 0 on Day 42

  32. Change From Baseline in Immune Cell Function at Day 14

    The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 14

  33. Change From Baseline in Reticulocyte Count at Day 2

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 2

  34. Change From Baseline in Reticulocyte Count at Day 4

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 4

  35. Change From Baseline in Reticulocyte Count at Day 7

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 7

  36. Change From Baseline in Reticulocyte Count at Day 10

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 10

  37. Change From Baseline in Reticulocyte Count at Day 15

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 15

  38. Change From Baseline in Reticulocyte Count at Day 21

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 21

  39. Change From Baseline in Reticulocyte Count at Day 28

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 28

  40. Change From Baseline in Reticulocyte Count at Day 42

    Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

    Time frame: Baseline (Within 7 days prior to Day 1), Day 42

  41. Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function

    Time frame: Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42

  42. Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)

    EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.

    Time frame: Day 14

Secondary outcomes

  1. Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14

    Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.

    Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14

  2. Number of Participants With Physician's Global Assessment (PGA) of Psoriasis

    Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).

    Time frame: Baseline (Within 7 days prior to Day 1) up to Day 14

  3. Gene Expression in Psoriatic Plaque Biopsies

    Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.

    Time frame: Day 14

  4. Immunohistochemistry From Psoriatic Plaque Biopsies

    Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.

    Time frame: Baseline (within 7 days prior to Day 1), Day 14

  5. Number of Participants With Keratin 16 (K16) Expression

    Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.

    Time frame: Baseline (within 7 days prior to Day 1) up to Day 14

  6. Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression

    Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.

    Time frame: Baseline (within 7 days prior to Day 1) up to Day 14

  7. Gene Expression in Peripheral Blood

    Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).

    Time frame: Day 14

07

Results

Posted Feb 20, 2013

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Started551099813
Completed55999813
Not completed0010000
Withdrew: Withdrawal by subject0010000

Outcome measures

PrimaryChange From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1
Reported as:
Mean · millisecond (msec)
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1
millisecond (msec)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 1372.20 ± 34.3348.47 ± 23.52369.40 ± 19.47375.74 ± 24.65383.96 ± 18.10371.29 ± 28.33370.95 ± 18.00
Change at HPD 1 on Day 1-6.33 ± 25.9115.73 ± 9.04-6.33 ± 21.672.70 ± 14.541.63 ± 14.09-2.79 ± 13.28-4.21 ± 12.61
PrimaryChange From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1
Reported as:
Mean · msec
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 2369.67 ± 33.78350.27 ± 20.76372.87 ± 21.10377.48 ± 24.26387.00 ± 18.81374.00 ± 26.75369.87 ± 17.53
Change at HPD 2 on Day 1-0.40 ± 26.399.80 ± 13.71-6.90 ± 22.22-0.15 ± 12.82-0.07 ± 9.40-1.58 ± 13.66-2.05 ± 16.76
PrimaryChange From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1
Reported as:
Mean · msec
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 4 (n=5,5,10,9,9,8,13)373.73 ± 31.71348.07 ± 23.34373.20 ± 21.78373.15 ± 20.46381.44 ± 20.02381.17 ± 26.96368.00 ± 18.04
Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13)-4.53 ± 23.1711.53 ± 12.322.19 ± 20.982.96 ± 17.947.74 ± 14.69-8.17 ± 14.32-2.82 ± 10.82
PrimaryChange From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1
Reported as:
Mean · msec
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 8 (n=5,5,10,9,9,8,13)364.13 ± 36.00356.73 ± 25.62366.90 ± 22.02374.56 ± 22.73378.15 ± 23.91372.25 ± 28.29367.56 ± 17.95
Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13)-1.27 ± 15.93-6.60 ± 10.71-3.96 ± 18.54-3.44 ± 12.757.67 ± 16.08-9.83 ± 15.12-9.03 ± 11.52
PrimaryChange From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1
Reported as:
Mean · msec
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 12 (n=5,5,10,9,9,8,13)371.73 ± 31.50351.27 ± 22.90372.63 ± 22.54370.11 ± 25.70379.78 ± 24.93363.08 ± 31.21361.54 ± 16.29
Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13)-6.27 ± 19.05-2.60 ± 5.27-4.15 ± 17.900.15 ± 9.79-3.22 ± 19.73-2.88 ± 14.01-1.36 ± 13.60
PrimaryChange From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo.

Time frame:
8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1
Reported as:
Mean · msec
Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1
msecCP-690,550 60 mg (Cohort 5)Placebo
Baseline for HPD 16377.15 ± 19.50345.44 ± 18.77
Change at HPD 16 on Day 111.19 ± 19.9813.11 ± 7.26
PrimaryChange From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0.

Time frame:
Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline for HPD 0374.80 ± 28.95360.40 ± 28.03367.70 ± 30.28372.81 ± 27.83383.41 ± 19.25367.50 ± 22.12364.03 ± 20.96
Change at HPD 0 on Day 14-14.53 ± 11.3911.00 ± 12.00-0.33 ± 14.087.22 ± 16.38-9.70 ± 13.15-0.79 ± 17.48-7.08 ± 16.21
PrimaryChange From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14-8.87 ± 12.1222.27 ± 13.720.11 ± 12.552.81 ± 15.98-0.96 ± 14.630.71 ± 20.43-12.87 ± 17.82
PrimaryChange From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14-3.80 ± 12.1818.67 ± 11.15-3.93 ± 13.216.89 ± 13.98-3.81 ± 17.182.46 ± 22.04-12.28 ± 19.35
PrimaryChange From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14-13.80 ± 15.376.53 ± 7.81-8.41 ± 7.2518.96 ± 18.559.59 ± 10.70-4.79 ± 21.58-8.46 ± 21.09
PrimaryChange From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14-9.33 ± 11.31-0.53 ± 9.83-6.15 ± 15.86-1.96 ± 13.754.85 ± 18.51-2.67 ± 23.28-12.36 ± 11.38
PrimaryChange From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.

Time frame:
12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14
Reported as:
Mean · msec
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14
msecCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14-13.47 ± 12.768.00 ± 8.48-10.52 ± 10.630.81 ± 13.99-7.44 ± 22.73-0.63 ± 23.46-4.82 ± 15.31
PrimaryNumber of Participants With Increase From Baseline in Corrected QT (QTc) Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.

Time frame:
1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Reported as:
Number · participants
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval
participantsCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
QTcB,Maximum increase from baseline:30 to <60msec0121325
QTcB,Maximum increase from baseline:>=60msec0000100
QTcF,Maximum increase from baseline:30 to <60msec0101301
QTcF,Maximum increase from baseline:>=60msec0000000
PrimaryNumber of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc \>=500 msec were reported.

Time frame:
1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21
Reported as:
Number · participants
Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond
participantsCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
QTcB0000000
QTcF0000000
PrimaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1

AUCtau = area under the curve from time zero to end of dosing interval.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Reported as:
Mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1
nanogram*hour/milliliter (ng*hr/mL)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1161 ± 86.1349 ± 34.7732 ± 232860 ± 2352120 ± 8371720 ± 453
PrimaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14

AUCtau = area under the curve from time zero to end of dosing interval.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14
ng*hr/mLCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14154 ± 80.3422 ± 49.5850 ± 2161350 ± 3082600 ± 15801780 ± 501
PrimaryMaximum Observed Plasma Concentration (Cmax) at Day 1
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Reported as:
Mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) at Day 1
nanogram/milliliter (ng/mL)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Maximum Observed Plasma Concentration (Cmax) at Day 148.3 ± 24.590.5 ± 20.4212 ± 62.3180 ± 53.1457 ± 88.2429 ± 99.1
PrimaryMaximum Observed Plasma Concentration (Cmax) at Day 14
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) at Day 14
ng/mLCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Maximum Observed Plasma Concentration (Cmax) at Day 1450.9 ± 21.287.7 ± 13.2194 ± 53.9225 ± 43.9568 ± 205403 ± 133
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1
hrCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 10.50 (0.25 to 1.00)0.50 (0.50 to 1.00)0.50 (0.25 to 2.00)0.50 (0.50 to 3.00)1.00 (0.50 to 3.00)1.00 (0.50 to 2.00)
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14
hrCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 140.50 (0.50 to 0.50)1.00 (0.50 to 1.00)0.50 (0.25 to 2.00)1.00 (0.50 to 4.00)1.00 (0.50 to 2.00)1.00 (0.50 to 2.00)
PrimaryAccumulation Ratio (R0)

Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14
Reported as:
Mean · Ratio
Accumulation Ratio (R0)
RatioCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)
Accumulation Ratio (R0)0.974 ± 0.1811.22 ± 0.2031.22 ± 0.3891.62 ± 0.3431.16 ± 0.2701.14 ± 0.176
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, 1 hr post-dose on Day 1
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 1: CD3-14.39 ± 14.612.02 ± 18.21.17 ± 17.712.44 ± 17.48.38 ± 23.912.83 ± 14.00.52 ± 16.5
Change at Day 1: CD4-18.48 ± 19.48.65 ± 23.5-4.29 ± 15.25.99 ± 15.6-1.13 ± 19.98.54 ± 10.71.35 ± 18.3
Change at Day 1: CD8-7.58 ± 11.026.05 ± 25.18.90 ± 22.118.34 ± 21.413.90 ± 21.925.44 ± 14.60.42 ± 16.5
Change at Day 1: CD16/5611.22 ± 27.079.99 ± 33.781.44 ± 62.774.07 ± 38.6104.44 ± 85.8103.74 ± 21.2-9.72 ± 18.3
Change at Day 1: CD19-27.11 ± 16.7-4.02 ± 30.9-10.30 ± 18.1-8.23 ± 10.4-6.22 ± 29.9-0.66 ± 9.0-6.46 ± 22.4
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 2
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 2: CD38.88 ± 24.034.74 ± 27.423.93 ± 31.146.07 ± 31.414.05 ± 24.452.43 ± 34.3-5.18 ± 17.4
Change at Day 2: CD48.58 ± 26.733.29 ± 25.426.73 ± 31.944.17 ± 33.918.85 ± 34.955.80 ± 35.5-6.85 ± 18.0
Change at Day 2: CD812.67 ± 19.332.68 ± 30.119.68 ± 29.343.04 ± 29.116.96 ± 25.150.97 ± 30.4-4.17 ± 20.2
Change at Day 2: CD16/5618.27 ± 30.461.26 ± 47.852.84 ± 54.863.21 ± 45.10.61 ± 37.7103.79 ± 45.85.61 ± 35.7
Change at Day 2: CD197.58 ± 40.39.56 ± 30.517.40 ± 24.530.39 ± 11.37.04 ± 33.545.72 ± 44.4-4.22 ± 24.4
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 4
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 4: CD3-15.29 ± 21.151.71 ± 31.429.11 ± 49.071.55 ± 44.534.28 ± 41.832.81 ± 28.03.80 ± 28.2
Change at Day 4: CD4-15.87 ± 22.443.87 ± 22.030.90 ± 51.772.02 ± 43.142.50 ± 56.739.46 ± 27.26.08 ± 31.3
Change at Day 4: CD8-10.94 ± 17.856.72 ± 43.518.18 ± 41.761.61 ± 41.431.95 ± 32.629.81 ± 33.5-0.31 ± 24.8
Change at Day 4: CD16/56-23.08 ± 22.590.73 ± 41.610.67 ± 44.324.27 ± 55.5-5.23 ± 43.2-1.66 ± 44.87.18 ± 59.8
Change at Day 4: CD19-12.59 ± 27.241.44 ± 18.253.84 ± 71.856.27 ± 35.144.76 ± 55.777.25 ± 50.7-2.55 ± 37.5
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 7
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 7: CD35.72 ± 20.628.15 ± 26.013.47 ± 55.425.51 ± 38.91.61 ± 26.034.77 ± 33.1-3.08 ± 17.3
Change at Day 7: CD46.52 ± 22.629.39 ± 22.214.99 ± 56.624.48 ± 39.30.91 ± 26.637.42 ± 33.1-3.28 ± 17.8
Change at Day 7: CD86.76 ± 18.531.50 ± 42.37.21 ± 50.121.74 ± 37.51.74 ± 25.230.95 ± 27.8-3.10 ± 19.8
Change at Day 7: CD16/56-10.57 ± 14.329.97 ± 56.617.02 ± 83.0-1.43 ± 40.0-2.37 ± 56.4-7.95 ± 30.22.26 ± 35.2
Change at Day 7: CD1913.01 ± 36.334.47 ± 24.655.54 ± 83.272.86 ± 67.415.14 ± 46.098.64 ± 102.9-2.40 ± 22.3
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 10
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 10: CD35.70 ± 18.98.76 ± 35.712.47 ± 49.136.76 ± 43.811.30 ± 50.012.61 ± 30.6-3.69 ± 27.9
Change at Day 10: CD46.86 ± 20.916.87 ± 34.014.50 ± 50.838.22 ± 43.014.61 ± 54.416.85 ± 32.4-4.52 ± 27.5
Change at Day 10: CD85.34 ± 20.94.13 ± 39.80.68 ± 35.428.77 ± 40.516.81 ± 62.47.87 ± 20.1-4.14 ± 30.6
Change at Day 10: CD16/56-16.73 ± 29.3-25.53 ± 41.4-16.22 ± 22.8-33.38 ± 27.2-21.99 ± 36.1-37.90 ± 24.8-10.82 ± 31.3
Change at Day 10: CD1924.06 ± 26.934.97 ± 38.776.05 ± 71.179.94 ± 69.263.64 ± 180.084.57 ± 109.7-13.19 ± 31.5
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline; hr 0, 8 hr post-dose on Day 14
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at 0 hr post dose on Day 14: CD31.01 ± 16.026.93 ± 21.57.07 ± 33.014.91 ± 32.110.74 ± 37.112.69 ± 43.9-15.05 ± 21.7
Change at 8 hr post dose on Day 14: CD37.98 ± 18.276.59 ± 28.719.79 ± 23.140.85 ± 36.744.08 ± 61.615.64 ± 32.3-7.20 ± 20.7
Change at 0 hr post dose on Day 14: CD4-1.91 ± 19.031.80 ± 11.09.86 ± 41.214.80 ± 32.39.67 ± 49.117.69 ± 46.8-15.51 ± 25.1
Change at 8 hr post dose on Day 14: CD47.31 ± 18.086.33 ± 30.322.68 ± 24.838.65 ± 36.757.94 ± 91.519.21 ± 30.4-5.88 ± 23.1
Change at 0 hr post dose on Day 14: CD86.92 ± 9.125.57 ± 37.0-3.36 ± 23.610.68 ± 30.917.58 ± 42.49.89 ± 35.5-14.21 ± 20.2
Change at 8 hr post dose on Day 14: CD810.36 ± 17.370.26 ± 34.016.37 ± 16.940.38 ± 34.442.59 ± 59.231.87 ± 86.9-6.94 ± 18.9
Change at 0 hr post dose on Day 14: CD16/56-0.34 ± 25.01.73 ± 52.8-28.06 ± 32.3-43.06 ± 21.4-20.03 ± 44.6-42.70 ± 35.0-6.49 ± 25.4
Change at 8 hr post dose on Day 14: CD16/56-8.06 ± 19.741.85 ± 47.4-6.44 ± 38.0-8.75 ± 46.545.94 ± 114.4-14.38 ± 37.9-4.09 ± 34.0
Change at 0 hr post dose on Day 14: CD1916.76 ± 25.139.97 ± 33.369.43 ± 75.968.14 ± 72.260.99 ± 151.4116.93 ± 215.8-16.04 ± 33.1
Change at 8 hr post dose on Day 14: CD1920.74 ± 19.892.47 ± 47.9117.56 ± 52.495.87 ± 86.678.60 ± 94.0152.66 ± 263.62.53 ± 36.2
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, Hour 0 on Day 18
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 18: CD313.89 ± 27.9-14.04 ± 30.6-10.24 ± 21.3-10.65 ± 18.5-14.54 ± 13.5-46.69 ± 17.53.91 ± 20.0
Change at Day 18: CD412.44 ± 29.6-13.35 ± 24.9-7.80 ± 21.5-8.89 ± 17.4-13.66 ± 19.1-42.60 ± 18.87.17 ± 17.1
Change at Day 18: CD817.52 ± 32.7-9.18 ± 44.1-12.38 ± 23.1-18.76 ± 24.0-13.47 ± 8.0-51.68 ± 18.14.70 ± 15.9
Change at Day 18: CD16/5611.58 ± 31.5-7.64 ± 73.7-21.03 ± 46.0-48.63 ± 63.5-17.13 ± 45.7-76.21 ± 28.2-0.68 ± 22.4
Change at Day 18: CD1916.98 ± 50.8-15.78 ± 15.913.95 ± 32.522.65 ± 45.8-8.14 ± 35.6-29.44 ± 25.4-4.67 ± 25.8
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 21
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 21: CD3-25.48 ± 10.5-6.38 ± 14.8-42.27 ± 23.9-14.82 ± 20.2-7.93 ± 13.5-27.37 ± 13.3-1.12 ± 17.8
Change at Day 21: CD4-29.75 ± 9.6-2.88 ± 7.4-41.01 ± 24.4-11.01 ± 20.7-9.41 ± 16.5-22.38 ± 13.11.16 ± 19.8
Change at Day 21: CD8-19.51 ± 14.0-6.00 ± 31.1-43.55 ± 28.9-23.78 ± 21.1-2.12 ± 14.8-32.49 ± 15.6-4.01 ± 17.8
Change at Day 21: CD16/56-7.23 ± 23.5-9.21 ± 63.8-47.87 ± 30.7-48.04 ± 19.05.62 ± 35.4-66.94 ± 19.2-2.22 ± 44.1
Change at Day 21: CD19-20.90 ± 25.4-14.61 ± 26.7-22.60 ± 26.6-7.67 ± 34.8-17.50 ± 27.7-12.51 ± 22.90.98 ± 24.3
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 28
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 28: CD3-18.11 ± 10.09.29 ± 24.50.38 ± 34.1-4.60 ± 17.9-7.60 ± 23.3-22.08 ± 9.7-2.57 ± 25.0
Change at Day 28: CD4-21.29 ± 13.310.97 ± 29.81.02 ± 35.2-5.90 ± 15.7-11.51 ± 19.8-19.90 ± 6.3-2.86 ± 24.9
Change at Day 28: CD8-11.96 ± 9.011.58 ± 18.8-2.84 ± 35.0-9.33 ± 18.5-6.13 ± 21.8-23.56 ± 13.7-1.56 ± 26.7
Change at Day 28: CD16/565.13 ± 35.921.93 ± 51.3-10.27 ± 31.2-28.52 ± 51.611.21 ± 55.9-26.96 ± 39.413.32 ± 50.8
Change at Day 28: CD19-7.96 ± 24.321.29 ± 23.51.96 ± 42.3-6.53 ± 21.8-16.50 ± 28.3-11.58 ± 22.1-12.51 ± 19.1
PrimaryPercent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42

Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1.

Time frame:
Baseline, hr 0 on Day 42
Reported as:
Mean · percent change
Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42
percent changeCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change at Day 42: CD3-20.79 ± 29.0-15.72 ± 29.9-11.58 ± 30.0-1.60 ± 19.5-9.17 ± 21.5-1.63 ± 20.20.19 ± 32.6
Change at Day 42: CD4-25.65 ± 30.3-19.27 ± 29.2-11.42 ± 30.0-4.08 ± 17.5-12.27 ± 24.6-3.81 ± 12.00.96 ± 35.7
Change at Day 42: CD8-12.74 ± 29.1-10.04 ± 37.2-12.93 ± 33.9-5.60 ± 19.8-3.24 ± 17.64.19 ± 31.43.57 ± 33.5
Change at Day 42: CD16/56-9.01 ± 25.421.15 ± 70.8-2.32 ± 27.92.87 ± 76.124.08 ± 35.8-4.54 ± 37.419.90 ± 41.5
Change at Day 42: CD19-31.86 ± 30.96.43 ± 33.6-9.39 ± 29.2-10.22 ± 27.3-20.20 ± 30.0-8.30 ± 16.8-3.93 ± 52.5
PrimaryChange From Baseline in Immune Cell Function at Day 14

The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (\<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, \>= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 14
Reported as:
Mean · ng/mL
Change From Baseline in Immune Cell Function at Day 14
ng/mLCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline: Stimulated ATP(n=2,5,10,9,9,7,13)222.75 ± 157.3205.40 ± 143.1429.00 ± 115.3406.11 ± 171.6210.56 ± 104.1252.50 ± 146.3301.88 ± 152.9
Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13)11.50 ± 9.910.60 ± 3.216.30 ± 6.616.44 ± 10.214.11 ± 8.37.14 ± 5.916.00 ± 12.4
Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13)92.75 ± 120.695.80 ± 135.0155.11 ± 168.090.11 ± 125.9118.78 ± 88.261.21 ± 124.726.81 ± 66.6
Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13)9.50 ± 2.85.60 ± 11.40.44 ± 8.90.33 ± 10.61.67 ± 15.40.29 ± 13.11.46 ± 11.2
PrimaryChange From Baseline in Reticulocyte Count at Day 2

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 2
Reported as:
Mean · 1000 cells/cubic millimeter (cells/mm^3)
Change From Baseline in Reticulocyte Count at Day 2
1000 cells/cubic millimeter (cells/mm^3)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Baseline (n=5,5,10,9,9,8,13)124.00 ± 30.694.00 ± 36.981.50 ± 20.195.22 ± 14.380.56 ± 24.479.75 ± 25.8100.69 ± 46.2
Change at Day 2 (n=5,5,9,9,8,8,12)-6.60 ± 21.3-2.00 ± 13.720.00 ± 16.1-17.67 ± 24.2-10.88 ± 19.7-3.75 ± 11.1-7.25 ± 28.8
PrimaryChange From Baseline in Reticulocyte Count at Day 4

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 4
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 4
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 4-14.00 ± 17.2-7.60 ± 16.517.33 ± 26.6-48.44 ± 13.3-14.67 ± 16.4-20.00 ± 14.9-20.85 ± 41.2
PrimaryChange From Baseline in Reticulocyte Count at Day 7

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 7
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 7
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 7-3.40 ± 18.76.40 ± 15.917.11 ± 26.5-14.44 ± 13.63.22 ± 20.6-30.38 ± 13.8-1.38 ± 31.1
PrimaryChange From Baseline in Reticulocyte Count at Day 10

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 10
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 10
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 10-16.40 ± 29.5-14.00 ± 18.316.00 ± 25.9-18.22 ± 15.96.56 ± 17.5-29.50 ± 21.5-3.42 ± 38.8
PrimaryChange From Baseline in Reticulocyte Count at Day 15

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 15
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 15
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 15-24.00 ± 25.3-11.40 ± 17.4-8.56 ± 11.9-42.22 ± 16.924.11 ± 16.8-31.57 ± 25.9-17.92 ± 28.4
PrimaryChange From Baseline in Reticulocyte Count at Day 21

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 21
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 21
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 21-13.40 ± 30.617.60 ± 11.544.22 ± 27.15.44 ± 14.440.25 ± 15.6-9.17 ± 23.912.54 ± 40.2
PrimaryChange From Baseline in Reticulocyte Count at Day 28

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 28
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 28
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 28-16.20 ± 8.247.60 ± 14.849.56 ± 24.023.89 ± 23.521.75 ± 13.656.00 ± 24.1-2.85 ± 32.5
PrimaryChange From Baseline in Reticulocyte Count at Day 42

Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis.

Time frame:
Baseline (Within 7 days prior to Day 1), Day 42
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Reticulocyte Count at Day 42
1000 cells/mm^3CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Change From Baseline in Reticulocyte Count at Day 42-4.60 ± 12.6-7.00 ± 35.934.56 ± 30.0-3.67 ± 12.5-2.33 ± 21.922.50 ± 31.7-18.00 ± 26.7
PrimaryTime to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function
Time frame:
Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42

No measurements were reported for this outcome.

PrimaryHalf Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)

EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured.

Time frame:
Day 14
Reported as:
Number · ng*hr/mL
Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)
ng*hr/mLAll CP-690,550 Treated Participants
Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50)2696
SecondaryNumber of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14

Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity.

Time frame:
Baseline (Within 7 days prior to Day 1) up to Day 14
Reported as:
Number · participants
Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14
participantsCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Erythema: 01002240
Erythema: 13487444
Erythema: 21110309
Erythema: 30000000
Erythema: 40000000
Induration: 00134161
Induration: 12353602
Induration: 22112229
Induration: 31000001
Induration: 40000000
Scaling: 00110250
Scaling: 13267328
Scaling: 22222414
Scaling: 30000001
Scaling: 40000000
SecondaryNumber of Participants With Physician's Global Assessment (PGA) of Psoriasis

Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis).

Time frame:
Baseline (Within 7 days prior to Day 1) up to Day 14
Reported as:
Number · participants
Number of Participants With Physician's Global Assessment (PGA) of Psoriasis
participantsCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
PGA:10000000
PGA:21000101
PGA:33132005
PGA:40321422
PGA:51024305
PGA:60122041
PGA:70000120
SecondaryGene Expression in Psoriatic Plaque Biopsies

Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC.

Time frame:
Day 14
Reported as:
Mean · relative expression unit (REU)
Gene Expression in Psoriatic Plaque Biopsies
relative expression unit (REU)CP-690,550 5 mg (Cohort 1)CP-690,550 30 mg (Cohort 4)Placebo
BCL-20.47 ± 0.090.36 ± 0.142.29 ± NA
BAX1.16 ± 0.210.83 ± 0.280.68 ± NA
CD257.34 ± 2.331.05 ± 0.270.16 ± NA
CXCL1015.03 ± 5.750.44 ± 0.450.04 ± NA
Granzyme B42.71 ± 18.541.20 ± 0.070.03 ± NA
IL-20.98 ± 0.160.87 ± 0.020.75 ± NA
IL-8556.12 ± 754.9114.66 ± NA0.00 ± NA
INOS77.79 ± 40.100.97 ± 0.080.02 ± NA
INF-gamma2.26 ± 1.490.90 ± 0.090.22 ± NA
IL-150.51 ± 0.010.70 ± 0.060.86 ± NA
IL-70.85 ± 0.111.26 ± 0.511.19 ± NA
K-1669.04 ± 7.605.18 ± 2.630.04 ± NA
PCNA2.09 ± 0.771.15 ± 0.060.41 ± NA
Perforin2.80 ± 2.560.65 ± 0.170.23 ± NA
TNF-FasL0.95 ± 0.241.24 ± 0.860.64 ± NA
SecondaryImmunohistochemistry From Psoriatic Plaque Biopsies

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo.

Time frame:
Baseline (within 7 days prior to Day 1), Day 14
Reported as:
Mean · cells/microliter (cells/μL)
Immunohistochemistry From Psoriatic Plaque Biopsies
cells/microliter (cells/μL)CP-690,550 5 mg (Cohort 1)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)Placebo
Baseline: CD3 epidermal (n=1,1,4,2)115.00 ± NA108.00 ± NA122.50 ± 50.8124.50 ± 55.9
Baseline: CD3 dermal (n=1,1,4,2)189.00 ± NA135.00 ± NA130.00 ± 81.3196.00 ± 99.0
Baseline: CD8 epidermal (n=1,1,4,2)66.00 ± NA55.00 ± NA108.50 ± 40.971.50 ± 19.1
Baseline: CD8 dermal (n=1,1,4,2)23.00 ± NA53.00 ± NA123.75 ± 103.674.00 ± 70.7
Baseline: CD83 epidermal (n=1,1,4,2)13.00 ± NA44.00 ± NA17.00 ± 12.11.50 ± 0.7
Baseline: CD83 dermal (n=1,1,4,2)11.00 ± NA78.00 ± NA18.00 ± 7.33.00 ± 0.0
Baseline: Absolute CD16/56 (n=0,0,0,0)NA ± NANA ± NANA ± NANA ± NA
Day 14: CD3 epidermal (n=1,1,4,2)148.00 ± NA96.00 ± NA82.25 ± 121.097.00 ± 41.0
Day 14: CD3 dermal (n=1,1,4,2)120.00 ± NA114.00 ± NA95.25 ± 59.492.00 ± 53.7
Day 14: CD8 epidermal (n=1,1,4,2)85.00 ± NA56.00 ± NA51.50 ± 50.841.50 ± 34.6
Day 14: CD8 dermal (n=1,1,4,2)27.00 ± NA42.00 ± NA90.50 ± 54.425.00 ± 9.9
Day 14: CD83 epidermal (n=1,1,4,2)42.00 ± NA11.00 ± NA1.25 ± 1.57.00 ± 9.9
Day 14: CD83 dermal (n=1,1,4,2)26.00 ± NA17.00 ± NA3.25 ± 2.29.50 ± 9.2
Day 14: Absolute CD16/56 (n=0,0,0,0)NA ± NANA ± NANA ± NANA ± NA
SecondaryNumber of Participants With Keratin 16 (K16) Expression

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes.

Time frame:
Baseline (within 7 days prior to Day 1) up to Day 14
Reported as:
Number · participants
Number of Participants With Keratin 16 (K16) Expression
participantsCP-690,550 5 mg (Cohort 1)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)Placebo
Baseline1142
Day 141142
SecondaryNumber of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression

Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes.

Time frame:
Baseline (within 7 days prior to Day 1) up to Day 14

No measurements were reported for this outcome.

SecondaryGene Expression in Peripheral Blood

Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 \[SF5\]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA).

Time frame:
Day 14
Reported as:
Mean · relative expression unit (REU)
Gene Expression in Peripheral Blood
relative expression unit (REU)CP-690,550 5 mg (Cohort 1)CP-690,550 30 mg (Cohort 4)Placebo
Granzyme B (n=9,9,6)0.69 ± 0.330.99 ± 0.581.58 ± 1.13
IFN-gamma (n=9,9,6)2.06 ± 1.581.16 ± 0.591.46 ± 0.86
TNF-SF5 (n=9,9,6)1.79 ± 1.141.29 ± 0.481.24 ± 0.38
TNF-FasL (n=9,9,6)0.99 ± 0.371.09 ± 0.531.27 ± 0.83
BCL2 (n=9,9,6)0.71 ± 0.400.90 ± 0.301.01 ± 0.22
BAX (n=9,9,6)1.10 ± 0.320.98 ± 0.250.97 ± 0.22
iNOS (n=2,1,1)77.79 ± 40.100.97 ± 0.080.02 ± NA
CD 25 (n=9,9,6)1.19 ± 0.501.02 ± 0.291.01 ± 0.24

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 5 mg (Cohort 1)—0/5 (0%)0/5 (0%)
CP-690,550 10 mg (Cohort 2)—1/5 (20%)1/5 (20%)
CP-690,550 20 mg (Cohort 3)—0/10 (0%)3/10 (30%)
CP-690,550 30 mg (Cohort 4)—0/9 (0%)1/9 (11.1%)
CP-690,550 60 mg (Cohort 5)—0/9 (0%)2/9 (22.2%)
CP-690,550 50 mg (Cohort 6)—0/8 (0%)2/8 (25%)
Placebo—0/13 (0%)2/13 (15.4%)
Most frequent serious events
Most frequent serious events
EventCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
Atrial fibrillationCardiac disorders0/51/50/100/90/90/80/13
Most frequent other events
Most frequent other events
EventCP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)Placebo
NauseaGastrointestinal disorders0/51/50/100/90/92/80/13
HeadacheGeneral disorders0/51/50/100/91/91/82/13
Lab test abnormalGeneral disorders0/50/50/101/90/90/80/13
PsoriasisSkin and subcutaneous tissue disorders0/50/50/100/91/90/80/13
Peripheral edemaMetabolism and nutrition disorders0/50/51/100/90/90/80/13
SGOT increasedMetabolism and nutrition disorders0/50/51/100/90/90/80/13
SGPT increasedMetabolism and nutrition disorders0/50/51/100/90/90/80/13
ArthrosisMusculoskeletal and connective tissue disorders0/50/51/100/90/90/80/13
InsomniaNervous system disorders0/50/50/100/90/90/81/13

Baseline characteristics

Age Continuous
Age Continuous(years)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)PlaceboTotal
Mean40.2 ± 12.843.8 ± 7.439.6 ± 11.144.6 ± 11.146.9 ± 10.247.1 ± 9.744.4 ± 10.443.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 5 mg (Cohort 1)CP-690,550 10 mg (Cohort 2)CP-690,550 20 mg (Cohort 3)CP-690,550 30 mg (Cohort 4)CP-690,550 60 mg (Cohort 5)CP-690,550 50 mg (Cohort 6)PlaceboTotal
Female323144522
Male237854837
08

Study locations

1 site
  • Pfizer Investigational Site
    Little Rock, Arkansas 72202, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 8 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Nov 29, 2012
Start
Nov 2002
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Results first posted
Feb 20, 2013
Last update
Feb 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01736696
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 29, 2012
Start date
Nov 2002
Primary completion
Apr 2004
Completion
Apr 2004
Results posted
Feb 20, 2013
Last update
Feb 20, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion